Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial

Maria Eugenia Toledo-Romani; Mayra Garcia-Carmenate; Carmen Valenzuela Silva; Waldemar Baldoquin-Rodriguez; Marisel Martinez Perez; Meiby C Rodriguez Gonzalez; Beatriz Paredes Moreno; Ivis Mendoza Hernandez; Raul Gonzalez-Mujica Romero; Oscar Samon Tabio; Pablo Velazco Villares; Juan Pablo Bacallao Castillo; Ernesto Licea Martin; Misladys Rodriguez Ortega,; Nuris Liem Herrera Marrero; Esperanza Caballero Gonzalez; Liudmila Ibelin Egues Torres; Reinaldo Duarte Gonzalez; Serguey Garcia Blanco; Suzette Perez Cabrera; Santos Huete Ferreira; Kirenia Idalmis Idalmis Cisnero; Omaida Fonte Galindo; Dania Melia Perez; Ivonne Rojas Remedios; Sonsire Fernandez Castillo; Yanet Climent Ruiz; Yury Valdes Balbin; Dagmar Garcia Rivera; vicente Verez-Bencomo

bioRxiv (2021) - Comments
doi: 10.1101/2021.10.31.21265703

Maria Eugenia Toledo-Romani, Mayra Garcia-Carmenate, Carmen Valenzuela Silva, Waldemar Baldoquin-Rodriguez, Marisel Martinez Perez, Meiby C Rodriguez Gonzalez, Beatriz Paredes Moreno, Ivis Mendoza Hernandez, Raul Gonzalez-Mujica Romero, Oscar Samon Tabio, Pablo Velazco Villares, Juan Pablo Bacallao Castillo, Ernesto Licea Martin, Misladys Rodriguez Ortega,, Nuris Liem Herrera Marrero, Esperanza Caballero Gonzalez, Liudmila Ibelin Egues Torres, Reinaldo Duarte Gonzalez, Serguey Garcia Blanco, Suzette Perez Cabrera